title: Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers.
abstract: This issue of Cancer Discovery features an article that describes distinct epigenetic mechanisms that operate in TMPRSS2-ERG fusion-negative prostate cancers. This finding clarifies molecular features of these TMPRSS2-ERG fusion-negative tumors and may have implications for how to treat this prostate cancer subtype.
authors.affiliation: Oregon Health & Science University, Knight Cancer Institute, Portland, OR 97239, USA. alumkalj@ohsu.edu
authors.forename: Joshi J
authors.initials: JJ
authors.lastname: Alumkal
authors.forename: James G
authors.initials: JG
authors.lastname: Herman
mesh_terms: D019175:DNA Methylation; D000071221:Enhancer of Zeste Homolog 2 Protein; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D063151:Polycomb Repressive Complex 2 / Q000235:genetics*; D011471:Prostatic Neoplasms / Q000235:genetics*
chemical_list: D000071221:Enhancer of Zeste Homolog 2 Protein; D035683:MicroRNAs; D015514:Oncogene Proteins, Fusion; D063151:Polycomb Repressive Complex 2; C528163:MIRN26 microRNA, human; C515553:TMPRSS2-ERG fusion protein, human; C498409:EZH2 protein, human